Doctor Julia Schoelermann
35Pharma Inc., Montreal (Canada)
Member of:
/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
HS135, a novel activin and GDF trap, is highly efficacious in preclinical models of pulmonary hypertension and obesity-associated heart failure with preserved ejection fraction
Event: ESC Congress 2023
Topic: Vascular Diseases
Session: Therapeutic strategies to combat vascular disease
